Anacor Pharmaceuticals, Inc.

Promentis Pharmaceuticals, Inc.

University of Alberta

James Nieman

Jacob J Plattner

Yong-Kang Zhang

Tsutomu Akama

Rajeshwar Singh

Stephen J Baker

Michael Richard Kevin Alley

Michael Neary

Daniel Lawton

Rashmi Sharma

Steven Paul Tanis

Vincent S Hernandez

Fernando Rock

Garry Robert Smith

D Lorne Tyrrell

Mostofa Hena

Alexandr Belovodskiy

Appan Srinivas Kandadai

Michael Houghton

Kirk R Maples

Virginia J Sanders

Robert Toms Jacobs

Yi Xia

Yvonne Freund

Daitao Chen

Charles Z Ding

Jack Jhamandas

Wen Fu

Marcelo Sales

Kamlesh Kumar Sahu

Ryoichi Kimura

Xiaosong Lu

Huchen Zhou

Michael A Joyce

Rahim Mohammad

Bing Bai

Elena Arutyunova

M Joanne Lemieux

Michael Richard Alley

James G Phillips

Tsutoma Akama

Minh Ha

El Mehdi Keramane

Garry Smith

The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

Compounds for the treatment of Alzheimer's disease

The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection. Aspects of the present disclosure also include methods of treating a Baltimore Group IV RNA virus infection in a subject. The present disclosure also provides pharmaceutical compositions related to the same.

RNA virus inhibitor compounds and uses thereof

Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Substituted N-acetyl-L-cysteine derivatives and related compounds

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Boron-containing small molecules

The compounds are of the class of 3,7 substituted benzoxaboroles, useful for killing and/or inhibiting the growth of microorganisms.

Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.

Cysteine prodrugs

A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof

Novel monosubstituted and disubstutituted oxaboroles and pharmaceutical compositions containing such oxaboroles are provided, which are useful for treating bacterial infections, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Boron containing small molecules

Compounds and methods of treating anti-inflammatory conditions are disclosed.

Boron-containing small molecules as anti-inflammatory agents

This invention provides, among other things, novel oxaboroles which are monosubstituted at the 3-, 6-, or 7-position, or disubstituted at the 3-/6- or 3-/7- positions, which are useful for treating bacterial infections, pharmaceutical compositions containing such oxaboroles, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Growing community of inventors

Sherwood Park, Canada

James Nieman